European Medical Journal

COPD in Never-Smokers May Be Distinct

COPD without smoking? New data reveal unexpected symptoms and inflammation patterns. Read more to see what this means for ...
ClickOnDetroit

What’s Going Around in Metro Detroit: Strep throat, stomach viruses, RSV, upper respiratory viruses

Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...

Are you breathing properly? How I found out I wasn’t

You might think of breathing as automatic, but dysfunctional breathing can arise even if you’re healthy ...
Chiang Rai Times

Chiang Mai Toxic Haze Raises Lung Risks as PM2.5 Worsens

April 2026 has brought one of the harshest Chiang Mai haze periods of the season. On April 4, PM2.5 reportedly spiked to 409 ug/m3 at Nakornping Hospital in ...
Naples Daily News on MSN

Brush fire smoke poses serious health risks: What to know

Brush fire smoke poses serious health risks, especially for those with lung or heart conditions, children, and the elderly.

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

UPMC Western Maryland doctor promotes pulmonary rehab

Dr. Javeria Anwar of UPMC Western Maryland has made it her mission to bring attention to the underutilization of pulmonary ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
PharmiWeb

Respiratory Diagnostics Market Set for Rapid Growth and Trend by 2026-2031

Introduction to the Global Respiratory Diagnostics MarketThe global respiratory diagnostics market is projected to expand at a steady growth rate of approximately 7% over the next five years, ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...